When Does a Lump in Neurofibromatosis Need Imaging? Nerve Sheath Tumours

Medically reviewed by Dr. Michael Kachur · Frankfurt, Germany·

You have counted these for years. In neurofibromatosis type 1 the lumps are part of the landscape, and almost all of them stay exactly what they are. So the question is never whether there is a lump. It is whether this one has changed. That answer only exists in a comparison, against last year's size, texture and scan, and holding that comparison straight across a lifetime is what Healz was built for.

Category
Health Insights
Date
Reading time
11 min
Share

The tumour behind the question is a malignant peripheral nerve sheath tumour, usually shortened to MPNST. It is uncommon, and it is why a new symptom in an old lump gets taken seriously. Most MPNSTs grow out of a plexiform neurofibroma that was already sitting there, per the ERN GENTURIS tumour surveillance guidelines for neurofibromatosis type 1 (eClinicalMedicine, 2023), which is why the deep ropey tumours are the ones under watch.

When Does a Lump in Neurofibromatosis Need Imaging? Nerve Sheath Tumours

Why most lumps in NF1 stay what they are

Neurofibromatosis type 1 occurs in about 1 in 3,000 to 4,000 people worldwide, per MedlinePlus Genetics, and the neurofibromas most adults develop are noncancerous tumours located on or just under the skin. Those small skin tumours are not what sends anyone for imaging. They can be numerous and new and still be the expected course.

The tumours that get monitored are the plexiform ones: deeper, spread along the length of a nerve, often present since childhood, sometimes large. That is why a plexiform tumour is examined at every clinic visit while the cutaneous ones are counted and left alone.

Ask Healz.

One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.

The numbers matter, because fear fills the gap where a number should be. ERN GENTURIS gives people with NF1 an 8 to 16 percent lifetime risk of developing an MPNST at any age, most often diagnosed between the ages of 20 and 40. The NCI PDQ health professional summary on childhood soft tissue sarcoma puts it from the oncology side: approximately 4 percent of patients with neurofibromatosis type 1 develop malignant peripheral nerve sheath tumours, which usually develop after a long latency, and some patients develop multiple lesions. The two count different populations over different spans, and both say the same thing to the person reading this. Most people with NF1 never develop one.

One middle category is worth knowing by name. An atypical neurofibromatous neoplasm of uncertain biologic potential, abbreviated ANNUBP and formerly called an atypical neurofibroma, sits between a benign plexiform neurofibroma and an MPNST. ERN GENTURIS treats a proven ANNUBP as a reason for surgery where that carries acceptable morbidity, and as a reason to count someone high risk afterwards.

Which changes in a lump actually warrant imaging?

ERN GENTURIS names four, and grades the recommendation strong. Anyone with NF1 who has any one of them should be investigated for an MPNST.

Growth. A rapid increase in the size of an existing plexiform neurofibroma, or a change in its growth rate. The second half carries as much weight as the first: a tumour that crept along for a decade and has started moving faster is a change in rate, even if the size is not yet dramatic.

Pain. New and persistent pain, pain at night, or substantial pain that is difficult to control. Night pain belongs here because this guideline puts it here for nerve sheath tumours in NF1, not because night pain is a general cancer signal.

A new neurological deficit. A new motor deficit, weakness or anything else the limb has stopped doing, or a new sensory deficit associated with any neurofibroma or peripheral nerve. ERN GENTURIS extends this explicitly to bladder function, bowel disturbance, swallowing problems and breathing difficulty, because a tumour on a deep nerve announces itself through function rather than through a lump you can feel.

Consistency. The development of a hard nodule inside a previously soft plexiform neurofibroma. Not the whole tumour turning firm. A discrete hard spot in something uniformly soft before.

That is the list. A lump that has held the same size and texture for years, with no pain and no change in function, is not what it describes. For children, ERN GENTURIS is direct about where the information comes from: parents can be questioned regarding any change in existing pain, growth or texture of the lesion, and in case of pain, change in texture or sudden increase in growth, the plexiform neurofibroma should be evaluated for possible malignant transformation. The parent's observation over months is the data, and nobody else has it.

What imaging is used, and why might a PET scan come into it?

Investigation begins with regional MRI of the area in question, per ERN GENTURIS. The NCI PDQ health professional summary calls MRI essential for extremity lesions. One MRI describes the tumour today, though, and the question is whether today differs from before, which is why the old report matters as much as the new one.

Then there is PET. ERN GENTURIS recommends that before surgery, MRI be carried out and FDG PET MRI (preferred) or FDG PET CT (if PET MRI is not available) be undertaken, using visual assessment together with semiquantitative assessment against a standardized uptake value cut-off. A large plexiform neurofibroma is not uniform, and if part of it has transformed, that part is metabolically busier than the rest; the combination of regional MRI and FDG PET helps identify lesions with a high suspicion for malignancy. PET is often there to point at the one region of a big tumour a needle should go into, not to deliver a verdict alone.

Whole body MRI plays a surveillance role rather than a diagnostic one. ERN GENTURIS recommends it at least once at the transition from childhood to adulthood, to measure internal tumour burden as a predictor of MPNST risk. If no internal plexiform neurofibromas show up then, further whole body MRI monitoring is not recommended, while localised imaging is still required at any age when symptoms suggest an MPNST. A normal whole body MRI at eighteen is not a licence to ignore a hard nodule at thirty.

Why is a biopsy planned rather than improvised?

Because a badly placed one costs the patient twice. ERN GENTURIS puts the decision in a specific place: where an ANNUBP or MPNST is suspected, primary resection is recommended if it is safe and feasible, and otherwise a radiologically guided diagnostic biopsy should be performed, taken at the discretion of a sarcoma multidisciplinary team, because these tumours can be heterogeneous and there is potential for a false negative result by missing malignant parts of the tumour. A sample from the wrong centimetre can come back reassuring and be wrong.

The second reason is surgical. The NCI PDQ health professional summary states that the surgeon who will perform the definitive resection needs to be involved in the biopsy decision where possible, because poorly placed incisional or needle biopsies may adversely affect the ability to achieve negative margins. The same summary says fine-needle biopsy is usually not recommended here, encourages open biopsy or multiple core-needle biopsies so enough tissue reaches histology and molecular testing, and notes that image guidance is particularly helpful in deep lesions. It also records what happens when a sarcoma is removed by someone who did not know it was one: in one analysis of adolescents and adults, unplanned initial excision resulted in an increased risk of local recurrence, metastasis and death.

None of that argues for waiting. ERN GENTURIS is blunt that there is no place for watchful waiting in MPNST, and that urgent surgical resection should be the mainstay of treatment where possible. Planned is not the opposite of fast. It means the right team moves once, in the right order. For the same reasoning applied to lumps outside NF1, see telling a benign lipoma from a sarcoma.

Who gets watched more closely

ERN GENTURIS lists the groups to be considered at high risk of MPNST, and membership changes how often you are seen rather than what you have: an NF1 microdeletion affecting SUZ12, missense variants affecting codons 844 to 848, a previous ANNUBP, a high internal tumour load on whole body MRI (or large or multiple plexiform neurofibromas where whole body MRI has not been done), neurofibromatous neuropathy, previous radiotherapy, and a relative with NF1 and an MPNST.

For children, the guideline advises annual assessment for complications of NF1 up to the age of ten and clinical assessment at least once every two years after that, with plexiform neurofibromas observed, palpated and neurologically examined at every visit by clinicians with NF1 expertise. Photography or video of a plexiform neurofibroma is named as a useful adjunct: a photograph taken today settles an argument in two years that memory cannot. When a pain rather than a lump is what changed, bone pain that is not just age walks through that version.

How Healz works a case like this

The problem in NF1 is not a shortage of records. It is that they live in different places, and the comparison nobody holds is the one that answers the question.

Healz puts the whole thing in one chat instead of ten apps, and what makes that worth doing is what sits inside it. Frontier AI works your case, so the MRI report, the earlier MRI report, the neurology notes and the pathology are read against each other rather than one document at a time. Healz is equipped with root-cause technology, so it does not stop at the first label on the page: it cross-checks your case against 1M+ rare cases and asks the questions a short appointment skips, which is exactly the gap here, where the finding is common and the dangerous version is rare. Healz's memory remembers every result you upload and connects the dots across years, so a lump's growth rate is measured against its own history and a hard nodule noted in one report does not get lost before the next scan. You can bring a board-certified doctor into the same chat for a second opinion.

Frequently asked questions

Can a neurofibroma turn into cancer?

A plexiform neurofibroma can. Most MPNSTs develop from a pre-existing plexiform neurofibroma, per ERN GENTURIS, and the lifetime risk across everyone with NF1 is 8 to 16 percent. The small cutaneous neurofibromas most adults with NF1 carry are noncancerous, per MedlinePlus Genetics.

What does a new hard lump inside a soft NF1 tumour mean?

It is one of the four findings ERN GENTURIS says should trigger investigation for an MPNST: a hard nodule in a previously soft plexiform neurofibroma. It does not mean cancer has been found. It means the lump has earned a regional MRI rather than another appointment six months out.

Should pain at night in NF1 be checked?

Yes. ERN GENTURIS lists pain that is new and persistent, nocturnal, or substantial and difficult to control among the signs that warrant investigation for a malignant nerve sheath tumour in NF1. Pain in a tumour that never hurt before is information whatever time it arrives.

Is a PET scan enough to diagnose a nerve sheath tumour?

No. ERN GENTURIS places FDG PET MRI or PET CT alongside MRI and clinical assessment before any discussion of biopsy, and the diagnosis still rests on tissue.

Does every adult with NF1 need a whole body MRI?

ERN GENTURIS recommends it at least once at the transition from childhood to adulthood, to measure internal tumour burden as a predictor of MPNST risk. If no internal plexiform neurofibromas are found then, repeat whole body MRI is not recommended and clinical assessment alone is enough. Symptoms still get localised imaging at any age.

In NF1 the lump was never the finding. The change is, and a change only shows up against a record that someone kept.

Written by Healz Team · Filed under Health Insights

Your health deserves more than guesswork

Get a real investigation, not a symptom list. Root causes found, history remembered, dots connected.

Not a medical provider. Healz.ai is an educational service. Always discuss every decision with your doctor. AI can make mistakes.

© 2026 HealzAI Inc1111B S Governors Ave #92123, Dover, DE 19904, USAMade with for better health